Cancer is a broad group of diseases involving unregulated cell growth with elevated death rates as more people live in old age with mass lifestyle changes occurring in the world. The causes of cancer are diverse, complex, and still only partially understood. The chances of surviving the disease vary remarkably by the type and location of the malignancy and the extent of disease at the start of treatment. Early cancer detection is proving to be a valid approach. Cancer can be detected in a number of ways, including the presence of certain signs and symptoms, screening tests, or medical imaging. Cancer therapy is dynamically changing and revision and change in patient management is constant as our knowledge increases. Cancer is routinely treated with chemotherapy, radiation therapy and surgery. Tailored cancer targeted therapy is becoming an emerging objective of today. In this book, a constructive group of cancer research experts bring the reader their shared vision, to give an extensive and realistic view of individual tumors such as breast, oral, prostate, gastric, and neuroendocrine tumors. New and contemporary terms and concepts in genetics and epigenetics, diet, anticancer treatments, and anticancer drug delivery systems are introduced in this volume. This reference highlights present experimental strategies and key findings that enhance our understanding of cancer and of future therapies. This eBook is aimed at a broad audience of undergraduates, medical students, PhDs, cancer researchers, and also cancer patient families with the goal to conceive a curiosity about the subjects presented that will hopefully lead to further studies.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of avastin's role in restricting malignant gliomas is also included giving readers a diverse perspective on the rationale of treating CNS tumors.

Cancer is a major cause of deaths all around the globe. Although numerous anticancer drugs are available, most of them are expensive and have serious side effects. Natural compounds are usually non-toxic and inexpensive. Many such compounds have been identified and explored for their health benefits for centuries, and several nutritional factors derived from natural products have attracted considerable attention as therapeutic agents for the prevention and treatment of cancer. Based on current available research, this ebook focuses on chemopreventive and anti-cancer activities of different natural/dietary compounds present in fruits, vegetable, spices, legumes, nuts, grains, and cereals. Contributions from authors around the world highlight the potential use of such derivatives against cancer treatment by presenting updated information of their biochemical mechanisms. Information in this book is intended for researchers, clinicians, patients, academicians, industrialists, and students seeking updated and critical information for their experimental plans (including clinical trials). The book also creates awareness among cancer patients, nutritionists and laymen about cost effective therapeutic alternatives available for cancer therapy.

Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters in this volume have been written by leading experts from the field. The contents of this book include new approaches to cancer therapy, treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors, targeting key signaling pathways in pediatric brain tumors, current status of cladribine in lymphoid and myeloid malignancies, natural anti-cancer products and the mechanisms of telomere and telomerase regulation in hematologic malignancies. The eBook series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.

Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters featured in each volume are written by leading experts in oncology and clinical pharmacology. The eBook series is essential reading for all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the development of anti-cancer agents. The contents of this volume include reviews on dendrimers for anti-cancer drug delivery, treatment methods for advanced cutaneous squamous cell carcinoma, targeting heat shock proteins for cancer treatment, Bayesian systems for optimizing treatment protocols in oncology and much more.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that covers extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fourth volume of the book brings forth reviews on biomarkers and new drugs used for treating gastrointestinal cancer and breast cancer. The volume also covers the topics of adjuvant therapy, cancer nanodrugs and the role of adiponectin and dicycloplatin in cancer therapy.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The sixth volume of the book features reviews on these topics: · Immunomodulating Agents in The Treatment of Acute Myeloid Leukemia · Potential Natural Products for Prostate Cancer Management · Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design · Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) For Advanced Hepatocellular Carcinoma · Targeting Cancer Stem Cells: Implications in Health and Disease

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics:

· Essential oils and monoterpenes as potential anti-cancer agents

· Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma

· CTDNA in solid tumors

· Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment